Risk Management

Giant cell arteritis checklist

Use a checklist to screen patients for giant cell arteritis (click download for document)

OMIC conducted a review* of claims for delay in diagnosis of giant cell arteritis [(GCA, also known as temporal arteritis). Our study of these claims showed that a careful review of signs, symptoms, and systems is needed to help distinguish the few patients who could have GCA from the large number of older patients with eye problems seen daily in ophthalmic practices. In 66% of the patients, ophthalmologists failed to elicit the non-vision related symptoms that patients were experiencing. The incomplete and inaccurate history led to a delay in diagnosis and treatment.

OMIC Board member Dr. Ronald W. Pelton, MD, PhD developed this Giant cell arteritis checklist  to prompt ophthalmologists to ask key questions and document both positive and negative findings. Please review it carefully and modify it to suit your practice and preferences. For example, you may choose to refer patients to an internist for steroid management rather than prescribe them yourself, or use a different dosage.

Giant cell arteritis claims are costly and difficult to defend

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment

Six reasons OMIC is the best choice for ophthalmologists in America.

#4. Largest insurer in the U.S.

OMIC is the largest insurer of ophthalmologists in the United States and we've been the only physician-owned carrier to continuously offer coverage in all states since 1987 (pending in WI). Our fully portable policy can be taken with you wherever you practice. Should you move to a new state or territory, you're covered without the cost or headache of applying for new coverage.